结直肠癌患者血清基质金属蛋白酶水平及其临床意义  

The Serum Levels of Matrix Metalloproteinases in Patients with Colorectal Cancer and Their Significances

作　　者：刘小野[1] 董浩[2,3,4,5,6] 荆瀛黎[2,3,4,5,6] 金岚[1] 王今[1] 吴国聪[1] 张忠涛[1] 

机构地区：[1]首都医科大学附属北京友谊医院,北京100050 [2]首都医科大学康复医学院,北京100068 [3]中国康复研究中心博爱医院,北京100068 [4]中国康复科学所,北京100068 [5]北京脑重大疾病研究院神经损伤与修复研究所,北京100068 [6]神经损伤与康复北京市重点实验室,北京100068

出　　处：《现代生物医学进展》2017年第1期48-50,35,共4页Progress in Modern Biomedicine

基　　金：北京脑重大疾病研究院科研促进项目(PXM2014_014226_000016);神经损伤与康复北京市重点实验室2015年度科技创新基地培育与发展专项项目(Z151100001615055);中央级公益性科研院所基本科研业务费专项资金项目(2015CZ-12)

摘　　要：目的:探讨结直肠癌患者血清基质金属蛋白酶水平及其临床意义。方法:采用Bio-plex200悬浮芯片系统检测33例结直肠癌患者(其中13例为结直肠癌转移患者,20例为结直肠癌非转移组)和30例正常对照组血清中基质金属蛋白酶(MMP)-1、2、3、7、8、9、10、12、13的浓度。结果:与正常对照组相比,结直肠癌患者血清MMP-2、MMP-7、MMP-8、MMP-9、MMP-10、MMP-13的浓度显著上调(P<0.05),而MMP-1、MMP-3、MMP-12的浓度并无显著性差异(P>0.05);与结直肠癌非转移组患者相比,结直肠癌转移组患者血清MMP-2和MMP-7的浓度显著升高(MMP-2:P=0.029;MMP-7:P=0.002)。结论:基质金属蛋白酶可能在结直肠癌的发生、发展过程中起重要作用;MMP-2和MMP-7可能成为结直肠癌发生和转移的预测和评估指标。Objective： To explore the serum levels of matrix metalloproteinases in patients with colorectal cancer and their significances. Methods： 33 colorectal cancer（CRC） patients and 30 healthy subjects were enrolled in this study. The serum levels of MMPs（（MMP）-1, 2, 3, 7, 8, 9, 10, 12, 13） were measured using Bio-plex Multiplex System. Results： Compared with the serum of cases with normal controls, the concentrations of MMP-2, MMP-7, MMP-8, MMP-9, MMP-10 and MMP-13 in serum of cases with colorectal cancer were significantly up-regulated（P〈0.05）, while the concentrations of MMP-1, MMP-3, MMP-12 showed no significance（P〈0.05）.Compared with the serum of colorectal cancer patients without metastasis, the concentrations of MMP-2 and MMP-7 in serum of colorectal cancer with metastasis were significantly up-regulated（MMP-2： P=0.029; MMP-7： P=0.002）. Conclusion： MMPs might play an important role in the development and occurrence of colorectal cancer, MMP-2 and MMP-7 might be used as indicators of predicting and evaluating the occurrence and metastasis of colorectal cancer.

关 键 词：结直肠癌 基质金属蛋白酶 悬浮芯片技术 

分 类 号：R735.3[医药卫生—肿瘤]